Insider selling
Traded Aug 26 · filed 5 days laterNot reported under a pre-arranged trading plan
An Alzamend Neuro director sold $3.1K of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 14, 2026 · Filed Aug 31, 2026
An Alzamend Neuro director paid $109K out of pocket for Alzamend Neuro shares. Shares held went up 1312% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$108,897
Shares × reported transaction price
$100K–$500K
+1312.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
Closed at $1.04 on Apr 14, 2026, 21% above its 52-week low and 85% below its high, after a 48% drop over the previous 30 trading days
52-week range $0.8575 (Apr 10, 2026) to $6.84 (Apr 15, 2025), 3% of the way up, from 250 adjusted closes. 30 trading days earlier: $2.01 on Mar 2, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.6% | +0.6% | +2.1% |
| 30 days | −19.7% | +0.3% | −19.9% |
Past results only. Not a forecast.
Insider selling
Traded Aug 26 · filed 5 days laterNot reported under a pre-arranged trading plan
An Alzamend Neuro director sold $3.1K of Alzamend Neuro shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Apr 14 · filed 139 days later
An Alzamend Neuro director paid $2.1K out of pocket for Alzamend Neuro shares.
Insider buying
First insider buy since Mar 2025Traded Apr 14 · filed 139 days later
An Alzamend Neuro director paid $2.1K out of pocket for Alzamend Neuro shares.
Milton C Iii Ault, Director's past purchases, 90 days after disclosure: 71 buys, median −32.0 pts vs S&P 500, beat it 24 of 71 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.